TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding TScan Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 60 | 60 | 0 |
| Shares | 32.5M | 35.8M | +3.33M (+10.3%) |
| Value | $32.8M | $35.1M | +$2.30M (+7.0%) |
New holders (7)
Institutions that held TScan Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Boothbay Fund Management, LLC | 772,241 | $756.9K | 0.01% |
| Kalehua Capital Management LLC | 454,876 | $445.8K | 0.26% |
| Mizuho Securities USA LLC | 205,600 | $201.5K | 0.00% |
| HRT Financial LP | 164,601 | $161.0K | 0.00% |
| Landscape Capital Management, L.L.C. | 25,864 | $25.3K | 0.00% |
| R Squared Ltd | 18,360 | $18.0K | 0.01% |
| Global Retirement Partners, LLC | 10,000 | $9.80K | 0.00% |
Sold out (7)
Institutions that held TScan Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Standard Life Aberdeen plc | 918,020 | $927.2K |
| Nine Masts Capital Ltd | 41,740 | $42.2K |
| Prudential Financial Inc | 29,800 | $30.1K |
| Panagora Asset Management Inc | 28,797 | $29.1K |
| LPL Financial LLC | 22,500 | $22.7K |
| Virtu Financial LLC | 18,140 | $18.0K |
| Citigroup Inc | 1 | $1 |